

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within a particular health board because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The ADTC, Grampian Area Drug and Therapeutics Committee, is responsible for advising NHS Grampian health board on all aspects of the use of medicines.

Medicines routinely available within NHS Grampian are usually included in the Grampian Joint Formulary. The formulary is a list of medicines for use in the health board that has been agreed by the ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. A formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

How does the health board decide which new medicines to make routinely available for patients?

The ADTC in a health board will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in a health board.

Why is a particular medicine not routinely available in NHS Grampian?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences as to which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

What happens if a particular medicine is not routinely available in NHS Grampian?

- If a medicine is not routinely available and not included in the Grampian Joint Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. All health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Grampian's latest decisions on medicines.

If you need more information on medicines decisions in NHS Grampian, please email gram.formularyteam@nhs.scot.

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](https://www.FreeDigitalPhotos.net)

This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
atezolizumab 840mg, 1,200mg concentrate for solution for infusion (Tecentriq®)	2492	As monotherapy as adjuvant treatment following complete resection for adult patients with Stage II to IIIA (7th edition of the UICC/AJCC staging system) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥50% of tumour cells and whose disease has not progressed following platinum-based adjuvant chemotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/08/2022
cenobamate 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg film-coated tablets (Ontozry®)	2408	As a second-line adjunctive treatment of focal-onset seizures with or without secondary generalisation in adults with drug-resistant epilepsy who have not been adequately controlled despite previous treatment.	Routinely available in line with national guidance, SMC 2408 https://www.scottishmedicines.org.uk/media/6671/cenobamate-ontozry-final-jan-2022-amended-180122-for-website.pdf	16/08/2022
crizanlizumab 10mg/mL concentrate for solution for infusion (Adakveo®)	2438	For the prevention of recurrent vaso-occlusive crises in sickle cell disease patients aged 16 years and older. It can be given as an add-on therapy to hydroxycarbamide or as monotherapy in patients for whom hydroxycarbamide is inappropriate or inadequate.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/08/2022
dapagliflozin 5mg, 10mg film-coated tablets (Forxiga®)	2428	For the treatment of chronic kidney disease in adults: - with an estimated glomerular filtration rate of ≥25 to ≤75 mL/min/1.73m ² at treatment initiation, and - are receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker (unless these are not tolerated or contraindicated), and - have a urine albumin creatinine ratio of at least 23mg/mmol, or type 2 diabetes mellitus or both Restriction: start treatment on the advice of a Renal Consultant/Physician	Routinely available in line with national guidance, SMC 2428 https://www.scottishmedicines.org.uk/media/6871/dapagliflozin-forxiga-final-april-2022-amended-290422-for-website.pdf	16/08/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
daratumumab 1,800mg solution for injection (Darzalex®)	2447	In combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/08/2022
delafloxacin 450mg tablets, 300mg powder for concentrate for solution for infusion (Quofenix®)	2453	<p>Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of this infection.</p> <p>SMC restriction: patients with suspected or confirmed polymicrobial infection following treatment failure or when standard antibacterial therapies are not suitable. Delafloxacin should be used on the advice of local microbiologists or specialists in infectious disease. Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/08/2022
Delstrigo® 100mg/300mg/245mg film-coated tablets (doravirine/lamivudine/tenofovir disoproxil fumarate)		<p>For the treatment of adolescents aged 12 years to <18 years weighing at least 35kg who are infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.</p> <p>Restriction: to be prescribed under the supervision of specialists in paediatric HIV.</p>	Routinely available in line with local guidance	16/08/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
doravirine 100mg film-coated tablets (Pifeltro®)		In combination with other antiretroviral medicinal products, for the treatment of adolescents aged 12 years to <18 years weighing at least 35kg infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. Restriction: to be prescribed under the supervision of specialists in paediatric HIV.	Routinely available in line with local guidance	16/08/2022
enfortumab vedotin 20mg, 30mg powder for concentrate for solution for infusion (Padcev®)	2505	As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor.	Not routinely available as not recommended for use in NHS Scotland, SMC 2505 https://www.scottishmedicines.org.uk/media/6984/enfortumab-vedotin-padcev-non-sub-final-june-2022-for-website.pdf	16/08/2022
Evotaz® 300mg/150mg film-coated tablets (atazanavir/cobicistat)		In combination with other antiretroviral medicinal products for the treatment of HIV 1 infected adolescents aged 12 years to <18 years weighing at least 35kg without known mutations associated with resistance to atazanavir.	Not routinely available as there is a local preference for alternative medicines	16/08/2022
metolazone 5mg tablets (Xaqua®)		For the treatment of adults with oedema related to: - kidney diseases, including the nephrotic syndrome and states of impaired renal function - congestive heart failure	Routinely available in line with local guidance	16/08/2022
mexiletine 167mg hard capsules (Namuscla®)	2307	For the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders.	Routinely available in line with national guidance, SMC 2307 https://www.scottishmedicines.org.uk/media/5655/mexiletine-namuscla-resub-final-nov-2020-for-website.pdf	16/08/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
odevixibat 200microgram, 400microgram, 600microgram, 1,200microgram hard capsules (Bylvay®)	2411	For the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older.	Not routinely available in NHS Grampian. If local need identified treatment is available through the National Services Scotland Ultra orphan medicines Risk Share Scheme.	16/08/2022
pegcetacoplan 1,080mg solution for infusion (Aspaveli®)	2451	In the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months. SMC restriction: under the advice of the national PNH service.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/08/2022
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2420	In combination with platinum and fluoropyrimidine based chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS \geq 10. Restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Routinely available in line with national guidance, SMC 2420 https://www.scottishmedicines.org.uk/media/6872/pembrolizumab-keytruda-final-april-2022-amended-4522-for-website.pdf	16/08/2022
remimazolam 20mg powder for solution for injection (Byfavo®)	2454	In adults for procedural sedation.	Not routinely available as not recommended for use in NHS Scotland, SMC 2454 https://www.scottishmedicines.org.uk/media/7040/remimazolam-byfavo-final-july-2022-for-website.pdf	16/08/2022
risdiplam 0.75mg/mL powder for oral solution (Evrysdi®)	2401	For the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA type 1, type 2 or type 3 or with one to four SMN2 [survival of motor neuron 2] copies.	Routinely available in line with national guidance, SMC 2401 https://www.scottishmedicines.org.uk/media/6976/risdiplam-evrysdi-final-jan-2022-amended-040722-for-website.pdf	16/08/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
roxadustat 20mg, 50mg, 70mg, 100mg, 150mg film-coated tablets (Evrenzo®)	2461	Treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD). SMC restriction: for use in patients who are non-dialysis dependent (NDD) at the time of treatment initiation.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/08/2022
Sibnaya [®] 8mEq/24mEq prolonged-release granules (potassium citrate/potassium hydrogen carbonate)	2409	For the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/08/2022
solriamfetol 75mg, 150mg film-coated tablets (Sunosi®)	2439	To improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). SMC restriction: for use in patients who have failed modafinil or have a contraindication or intolerance to modafinil.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/08/2022
somatropin 24mg, 60mg solution for injection in pre-filled pen (Ngenla®)	2493	For the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/08/2022
trastuzumab deruxtecan 100mg powder for concentrate for solution for infusion (Enhertu®)	2388	As monotherapy for the treatment of adults with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received two or more prior anti-HER2-based regimens.	Routinely available in line with national guidance, SMC 2388 https://www.scottishmedicines.org.uk/media/6590/trastuzumab-deruxtecan-enhertu-final-december-2021docx-amended-241221docx-for-website.pdf	16/08/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Trimbow® 172micrograms/5micrograms/9micrograms pressurised inhalation solution (beclometasone dipropionate/ formoterol fumarate dihydrate/ glycopyrronium)	2334	Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/08/2022
tucatinib 50mg, 150mg film-coated tablets (Tukysa®)	2398	In combination with trastuzumab and capecitabine for the treatment of adults with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.	Routinely available in line with national guidance, SMC 2398 https://www.scottishmedicines.org.uk/media/6591/tucatinib-tukysa-final-december-2021docx-for-website.pdf	16/08/2022
vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio®)	2506	Treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 2506 https://www.scottishmedicines.org.uk/media/6987/vedolizumab-entyvio-non-sub-final-june-2022-for-website.pdf	16/08/2022